Roche Diagnostics leaps 7%; ERBA swings to a profit;

@FierceMedDev: Med tech VC Santé wraps up a $139M healthcare fund. Piece | Follow @FierceMedDev

@VarunSaxena2: Abbott's diabetes biz hit with its third Class I recall in a year. News | Follow @VarunSaxena2

@EmilyWFierce: Devices approved for pediatric use weren't tested in children first, new study finds. More | Follow @EmilyWFierce

@MichaelGFierce: ICYMI: 'Computer' made with DNA nanorobots delivers compounds in live cockroach. Story | Follow @MichaelGFierce

> Roche's ($RHHBY) diagnostics revenue jumped 7% in the first quarter, pulling in about $2.8 billion. News

> ERBA Diagnostics ($ERB) swung to a small profit in 2013 after taking a $1.5 million loss the previous year. Story

> Kalila Medical struck up a financing deal with Mérieux Développement that will help fund its work on a steerable sheath for electrophysiology procedures. More

Biotech News

@FierceBiotech: GlaxoSmithKline wins an FDA nod for its new #diabetes drug. More | Follow @FierceBiotech

@JohnCFierce: Little Lexicon posts positive diabetes data as rival pharma giants race ahead. Story | Follow @JohnCFierce

@DamianFierce: J&J's diagnostics business slipped another 7.1% on its way out the door. News | Follow @DamianFierce

@EmilyMFierce: New vaccine could guard against common birth defect-causing virus. Article | Follow @EmilyMFierce

> Merck bags FDA approval for its grass pollen pill Grastek. Story

> Roche adds a slate of PhIII schizophrenia trial failures to bitopertin's obituary. More

> Startup AAVLife sets sights on ataxia with $12M and a novel gene therapy. Article

Pharma News

@FiercePharma: Top-read on FiercePharma Monday: New attention disorder could equal a big new ADHD drug market. But is it legit? Story | Follow @FiercePharma

@TracyStaton: Juicy trade-secrets dispute between Bristol-Myers + its ad agency and an account manager who jumped ship. More from MediaPost | Follow @TracyStaton

@EricPFierce: A Patheon (now DPx) plant that had been up for sale gets a $300M infusion to make Exparel for Pacira. Article | Follow @EricPFierce

@CarlyHFierce: J&J Q1 sales tally 18.1 billion... read more here. Release | Follow @CarlyHFierce

> Roche cancer drugs Perjeta and Kadcyla drive strong Q1 results. Story

> Novartis marks 235 admin jobs for deletion amid companywide restructuring. News

> New drugs are J&J's Q1 heroes, spurring pharma giant to hike 2014 forecast. More

Biotech Research News

> Essential immune organ regenerated in mice. Story

> 3-D printed tumor mimics cancer better than 2-D model. Piece

> High protein levels linked to cell death in Parkinson's. More

> New vaccine could guard against common birth defect-causing virus. Article

> Plush 'carpets' of Silly Putty ingredient help stem cells grow. Feature

> UCSF rolls out patient database to boost brain research. Item

Pharma Manufacturing News

> Teva recalling more than 1M bottles of generic Cymbalta. Story

> FDA tags yet another Indian drugmaker, Canton Labs, with ban. More

> Plant that Patheon wanted to sell gets $300M investment. Article

> Impax believes manufacturing issues are fixed. News

> FDA bans Baxter plant that makes saline solution. Item

> ViiV recalls 1,000 bottles of Tivicay for cross-contamination. Report

Suggested Articles

A decade-long study found that patients with early breast cancer may be spared radiation procedures that span the whole breast.

A cell therapy for Parkinson’s disease starts out simple, but quickly gets complicated with the potential for immune responses and cancer mutations.

Johnson & Johnson Vision announced that the worldwide president of its surgical business, Tom Frinzi, plans to retire at the end of this year.